Geron appoints Alan Colowick as president, oncology
Geron Corporation announced the appointment of Alan B. Colowick, M.D., M.P.H., as president, oncology. In this newly created position, Dr. Colowick, 44, will manage the operational and strategic activities of the company's oncology programs. He will report to Dr. Thomas Okarma, Geron's president and CEO.
Prior to joining Geron, Dr. Colowick was the chief medical officer of Threshold Pharmaceuticals Inc., where he was responsible for all aspects of non-clinical and clinical development and manufacturing. Before this, he held a wide range of positions with Amgen Inc. Most recently, he served as vice president of European Medical Affairs.
Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Dana Farber Cancer Institute. He earned his M.P.H. at the Harvard School of Public Health and his M.D. at Stanford University School of Medicine.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
